Evolution of anticancer drug discovery and the role of cell-based screening.

[1]  J B Gibbs,et al.  Anticancer drug targets: growth factors and growth factor signaling. , 2000, The Journal of clinical investigation.

[2]  J. Weinstein,et al.  Molecular targets in cancer drug discovery: cell-based profiling. , 2000, Current pharmaceutical design.

[3]  J. Drews.  Drug discovery: a historical perspective. , 2000, Science.

[4]  W. Kaelin.  Choosing anticancer drug targets in the postgenomic era. , 1999, The Journal of clinical investigation.

[5]  D. Scudiero,et al.  Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. , 1991, Journal of the National Cancer Institute.

[6]  J. Gibbs.  Mechanism-based target identification and drug discovery in cancer research. , 2000, Science.

[7]  L. Hartwell,et al.  Integrating genetic approaches into the discovery of anticancer drugs. , 1997, Science.

[8]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[9]  Sigrid Stroobants,et al.  Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study , 2001, The Lancet.

[10]  J. Harper,et al.  Anticancer drug targets: cell cycle and checkpoint control. , 1999, The Journal of clinical investigation.

[11]  G. S. Johnson,et al.  An Information-Intensive Approach to the Molecular Pharmacology of Cancer , 1997, Science.

[12]  A. Balmain,et al.  How many mutations are required for tumorigenesis? implications from human cancer data , 1993 .

[13]  P. Szankasi,et al.  Cell-based assays for identification of novel double-strand break-inducing agents. , 2002, Journal of the National Cancer Institute.

[14]  Z. Wang,et al.  Treatment of acute promyelocytic leukemia with all-trans retinoic acid. A five-year experience. , 1993, Chinese Medical Journal.

[15]  L. Degos,et al.  Treatment of acute promyelocytic leukemia with all- trans retinoic acid , 2000 .

[16]  B. Druker,et al.  Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. , 2000, The Journal of clinical investigation.

[17]  C. Bloomfield,et al.  All-trans-retinoic acid in acute promyelocytic leukemia. , 1997, The New England journal of medicine.

[18]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[19]  E. Sausville,et al.  Molecules for the millennium: how will they look? New drug discovery year 2000 , 2000, British Journal of Cancer.

[20]  W. Sellers,et al.  Apoptosis and cancer drug targeting. , 1999, The Journal of clinical investigation.